This HTML5 document contains 40 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n13http://linked.opendata.cz/resource/drugbank/drug/DB08994/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n4http://linked.opendata.cz/ontology/drugbank/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/resource/drugbank/drug/DB08994/identifier/kegg-drug/
n7http://www.drugs.com/international/
n14http://linked.opendata.cz/resource/drugbank/drug/DB08994/identifier/drugbank/
n9http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08994
rdf:type
n4:Drug
n4:description
Ditazole is a non-steroidal anti-inflammatory agent with analgesic and antipyretic activity similar to phenylbutazone. Additionally, ditazole is a platelet aggregation inhibitor marketed in Spain and Portugal with trade name Ageroplas.
n4:group
approved withdrawn
owl:sameAs
n11:DB08994
dcterms:title
Ditazole
adms:identifier
n13:Ditazole n14:DB08994 n15:D07138
n4:synonym
2,2'-(4,5-Diphenyloxazol-2-ylazanediyl)diethanol S-222
foaf:page
n7:ditazole.html
n4:IUPAC-Name
n5:271B6317-363D-11E5-9242-09173F13E4C5
n4:InChI
n5:271B631D-363D-11E5-9242-09173F13E4C5
n4:Molecular-Formula
n5:271B631C-363D-11E5-9242-09173F13E4C5
n4:Molecular-Weight
n5:271B6319-363D-11E5-9242-09173F13E4C5
n4:Monoisotopic-Weight
n5:271B631A-363D-11E5-9242-09173F13E4C5
n4:SMILES
n5:271B631B-363D-11E5-9242-09173F13E4C5
n4:Water-Solubility
n5:271B6315-363D-11E5-9242-09173F13E4C5
n4:logP
n5:271B6313-363D-11E5-9242-09173F13E4C5 n5:271B6316-363D-11E5-9242-09173F13E4C5
n4:logS
n5:271B6314-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:B01AC01
n4:H-Bond-Acceptor-Count
n5:271B6323-363D-11E5-9242-09173F13E4C5
n4:H-Bond-Donor-Count
n5:271B6324-363D-11E5-9242-09173F13E4C5
n4:InChIKey
n5:271B631E-363D-11E5-9242-09173F13E4C5
n4:Polar-Surface-Area--PSA-
n5:271B631F-363D-11E5-9242-09173F13E4C5
n4:Polarizability
n5:271B6321-363D-11E5-9242-09173F13E4C5
n4:Refractivity
n5:271B6320-363D-11E5-9242-09173F13E4C5
n4:Rotatable-Bond-Count
n5:271B6322-363D-11E5-9242-09173F13E4C5
n4:casRegistryNumber
18471-20-0
n4:Bioavailability
n5:271B6329-363D-11E5-9242-09173F13E4C5
n4:Ghose-Filter
n5:271B632B-363D-11E5-9242-09173F13E4C5
n4:MDDR-Like-Rule
n5:271B632C-363D-11E5-9242-09173F13E4C5
n4:Number-of-Rings
n5:271B6328-363D-11E5-9242-09173F13E4C5
n4:Physiological-Charge
n5:271B6327-363D-11E5-9242-09173F13E4C5
n4:Rule-of-Five
n5:271B632A-363D-11E5-9242-09173F13E4C5
n4:Traditional-IUPAC-Name
n5:271B6318-363D-11E5-9242-09173F13E4C5
n4:pKa--strongest-acidic-
n5:271B6325-363D-11E5-9242-09173F13E4C5
n4:pKa--strongest-basic-
n5:271B6326-363D-11E5-9242-09173F13E4C5